Company intelligence

AMRX

Amneal Pharmaceuticals, Inc. · NYSE · Healthcare

Price$17.25+1.17% · +$0.20

Market cap5.51BEquity value

P / E19.2Trailing ratio

Volume1.47MLatest session

Market data

AMRX price chart

TradingView

Related signals

1 min delayed

Browse public AMRX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

AMRXApr 22, 2026-2.23% since signal

Amneal's Acquisition of Kashiv Positions It for Biosimilars Growth

Amneal Pharmaceuticals has agreed to acquire Kashiv BioSciences, aiming to create a leading biosimilars platform. This strategic move is set to strengthen Amneal's position in the market for affordable medicines and accelerate its biosimilar pipeline, potentially enhancing future revenue streams.

View signal analysis

AMRXMay 15, 2025+3.74% since signal

US FDA approves Amneal's migraine treatment

FDA approves Amneal's self-administered migraine drug. This approval could enhance AMRX's product portfolio and revenue.

View signal analysis

AMRXFeb 24, 2025+0.29% since signal

Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock

J.P. Morgan upgraded AMRX due to its strong generics business. Crexont’s launch reinforced this view. FDA approved Crexont for Parkinson’s; prescriptions neared 1,000 per week. Growth is evident. Crexont now captures 15% of Rytary’s volume. Revenue projections have risen significantly. AMRX shifted from simple tablets to complex generics. Q4 earnings report and raised target support long-term growth.

View signal analysis

Research